Baxter’s Rixubis Receives FDA Approval for Treating Hemophilia

The US Food and Drug Administration revealed that it has approved Baxter’s genetically engineered protein, Rixubis, for treating patients suffering from a form of the chronic blood disorder hemophilia.

Figures released by the National Hemophilia Foundation reveals that hemophilia B is the second most common type of hemophilia and affects around 25,000 people across the globe.

Hemophilia - Causes - Treatment - Genetic Testing - Support Groups
Hemophilia is a rare single gene, X- linked disorder, which tends to run in families.

The condition is caused when the patients fail to produce enough quantity of blood clotting factor needed for natural control of bleeding. Rixubis is the first new treatment approved in the last 15 years for treating hemophilia and is to be administered twice weekly.

“Rixubis is a welcome addition to our leading portfolio of hemophilia treatments, providing a much-needed treatment option for the thousands of people living with hemophilia B. This approval moves us one significant step forward in our pursuit of a bleed-free world, one patient at a time”, the president of Baxter's BioScience business, Ludwig Hantson said.

Patients With Severe Hemophilia At Risk Of Developing Osteoporosis
A new study suggests that children with hemophilia arthropathy, a severe form of hemophilia that causes joint pain and swelling, are more at risk

Source-Medindia

FDA Starts Review of Biogen�s Therapy for Hemophilia B
The US Food and Drug Administration is currently reviewing Biogen Idec’s application for a fusion protein therapy.

World Hemophilia Day 2013
World hemophilia day is celebrated on the 17th of April each year. The theme for 2013 is close the gap of hemophilia care globally.